DNA Vaccine for Ragweed Allergic Adults
A Phase II Observer-blind, Randomized, Placebo-Controlled Study of the Efficacy, Safety, Tolerability, and Immunogenicity of Subcutaneously Administered Dynavax Amb a 1 Immunostimulatory Oligodeoxyribonucleotide Conjugate (AIC) in Ragweed-Allergic Adults (Sponsor's Protocol NRH01)
Sponsor: Johns Hopkins University
This PHASE2 trial investigates Seasonal Allergic Rhinitis and is currently completed. Johns Hopkins University leads this study, which shows 8 recorded versions since 2001 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2019 — Jan 2021 [monthly]
Completed PHASE2
Status: Withdrawn → Completed
-
Jun 2018 — Jan 2019 [monthly]
Withdrawn PHASE2
▶ Show 3 earlier versions
-
May 2018 — Jun 2018 [monthly]
Withdrawn PHASE2
-
Sep 2017 — May 2018 [monthly]
Withdrawn PHASE2
Status: Completed → Withdrawn
-
Jan 2017 — Sep 2017 [monthly]
Completed PHASE2
First recorded
May 2001
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Johns Hopkins University
For direct contact, visit the study record on ClinicalTrials.gov .